Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06425302 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma
A Phase 2 study of Lymphoma, Follicular, sponsored by Celgene.
- Active
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
- 20
- Study locations
NCT06425302 is a Phase 2 study of Lymphoma, Follicular that is active but no longer recruiting, run by Celgene. The registered enrollment target is 90 participants, below the 122-participant average among 9 other Lymphoma, Follicular trials with a reported enrollment target (26% lower). The trial reports 20 study locations across 15 states.
The verdict
NCT06425302, a Phase 2 study of Lymphoma, Follicular, is active but no longer recruiting, sponsored by Celgene.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the efficacy and safety of golcadomide in combination with rituximab in participants with newly diagnosed advanced stage Follicular Lymphoma (FL).
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Doxorubicin
- DRUG Rituximab
- DRUG Vincristine
- DRUG Golcadomide
Study Locations (20)
Florida
- Local Institution - 0209 - Fort Myers
- Local Institution - 0005 - Jacksonville
- Local Institution - 0210 - St. Petersburg
- Local Institution - 0026 - Tampa
- Local Institution - 0208 - West Palm Beach
Arizona
- Local Institution - 0180 - Phoenix
- Local Institution - 0190 - Tucson
Alabama
- Local Institution - 0152 - Birmingham
Alaska
- Local Institution - 0055 - Anchorage
California
- Local Institution - 0035 - San Francisco
District of Columbia
- Local Institution - 0022 - Washington D.C.
Kansas
- Local Institution - 0019 - Westwood
Minnesota
- Local Institution - 0031 - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2024-08-30 |
| Est. Completion | 2028-11-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06425302
The ClinicalTrials.gov registry entry for NCT06425302 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 122-participant average among 9 other Lymphoma, Follicular trials with a reported enrollment target (26% lower). The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lymphoma, Follicular appearing as the primary indexed condition, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT06425302 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Florida, Arizona, Alabama.
Frequently Asked Questions
What is clinical trial NCT06425302 about?
NCT06425302 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma". The purpose of this study is to assess the efficacy and safety of golcadomide in combination with rituximab in participants with newly diagnosed advanced stage Follicular Lymphoma (FL).
What is the current status of trial NCT06425302?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2024-08-30. Estimated completion is 2028-11-27.
What conditions does trial NCT06425302 study?
This clinical trial studies the following conditions: Lymphoma, Follicular.
What interventions are being tested in trial NCT06425302?
The interventions under investigation include: Cyclophosphamide (DRUG), Doxorubicin (DRUG), Rituximab (DRUG), Vincristine (DRUG), Golcadomide (DRUG).
Who is sponsoring clinical trial NCT06425302?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06425302 being conducted?
This trial has 20 study locations across Alabama, Alaska, Arizona, California, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma, Follicular
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular Lymphoma
ACTIVE NOT RECRUITING · Phase 2
-
Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603)
COMPLETED · Phase 2
-
A Study of Enzastaurin in Participants With Follicular Lymphoma
COMPLETED · Phase 2
-
A Study of Rituximab and Bevacizumab in Patients With Follicular Non-Hodgkin's Lymphoma
COMPLETED · Phase 2
-
Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)
COMPLETED · Phase 2
-
A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in Patients With Low Tumor Burden Follicular Lymphoma
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.